Table 1. Patient Characteristics.
| Characteristics | Number of patients | Percentage |
| Gender | ||
| Male | 16 | 69.6 |
| Female | 7 | 30.4 |
| TNM stage at diagnosis | ||
| 1 (T1a/T1b) | 4 | 17.4 |
| 2 (T2) | 5 | 21.7 |
| 3 (T3a/T3b) | 14 | 60.9 |
| Fuhrman grade | ||
| 1 | 3 | 13.1 |
| 2 | 5 | 21.7 |
| 3 | 7 | 30.4 |
| 4 | 8 | 34.8 |
| ECOG Performance Status | ||
| 0 | 19 | 82.6 |
| 1 | 4 | 17.4 |
| Sites of metastases* | ||
| Lung | 15 | 48.4 |
| Bone | 6 | 19.3 |
| Lymph nodes | 5 | 16.1 |
| Other (liver, kidney) | 5 | 16.1 |
| MSKCC risk factor | ||
| Favorable | 10 | 43.5 |
| Intermediate | 11 | 47.8 |
| Poor | 2 | 8.7 |
| Treatment response at three months | ||
| Failure | 5 | 21.7 |
| Partial response (PR) | 9 | 39.1 |
| Stable disease (SD) | 9 | 39.1 |
MSKCC: Memorial Sloan-Kettering Cancer Center; ECOG: Eastern Cooperative Oncology Group.
*Several sites per patient.